Last update June 10, 2018

Erdosteine

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

A thiolactone derivative mucolytic agent of the natural amino acid homocysteine indicated in chronic obstructive bronchitis (CECMED 2017). Administered orally every 12 hours.

Since the last update we have not found published data on its excretion in breastmilk.

Its short half-life makes transfer to milk in significant quantities unlikely.

Side effects are gastrointestinal and mild.

This drug has very few bibliographic references and its effectiveness has not been proven (Cazzola 2018, Welsh 2015, Irwin 1993).

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

If you wish to minimize exposure, you should wait about 3 hours to breastfeed after administration.

Alternatives

  • Acetylcysteine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ambroxol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Bromhexine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Carbocisteine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Erdosteine is also known as


Erdosteine in other languages or writings:

Group

Erdosteine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Erdosteine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Alta - Hig %
Molecular weight 249 daltons
Protein Binding 65 %
Tmax 1,2 hours
T1/2 1,5 hours

References

  1. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulm Pharmacol Ther. 2018 Abstract
  2. CECMED. Erdosteína (Dostein). Ficha técnica. 2017 Full text (in our servers)
  3. Welsh EJ, Evans DJ, Fowler SJ, Spencer S. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2015 Abstract
  4. Irwin RS, Curley FJ, Bennett FM. Appropriate use of antitussives and protussives. A practical review. Drugs. 1993 Abstract

Total visits

15,314

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM